Introduction
============

With the improvement of imaging techniques, pancreas metastases are much more frequent than commonly appreciated. There were limited data about pancreas metastases of small cell lung cancer. Few guidelines are available on the appropriate management of such cases. The aim of this study is to review the pancreatic involvement due to small cell carcinoma of the lung.

Methods
=======

A computerised research of literature (English language only) was performed to identify the relevant articles dealing with the subject. Using the medical subject headings and terms "pancreas metastasis or pancreatic metastases", "small cell", and "lung" we reviewed *PubMed* and *Web of science* databases between 1970 and 2012. The selection criteria included patients with published demographic and clinical data regarding the treatment for cancer metastasized to pancreas. Exclusion criteria for this research included publications of patients' data in non-English language, patients without previous translation and lack of relevance of the analysis of pancreatic metastasis. Each paper was inspected and the reference lists of the selected articles were also screened systematically for additional studies of interest. More than 20 cases of primary small cell carcinoma of the pancreas were excluded.[@b1-rado-48-01-11]--[@b6-rado-48-01-11] Additionally, some cases with small cell cancer in the studies were analysed just to some extent because they did not describe the detailed clinical findings [@b7-rado-48-01-11]--[@b18-rado-48-01-11] Information regarding patient presentation, site of primary neoplasia, characteristics of metastasis in the pancreas, treatment, and patient demographics were summarised using descriptive statistics. All tests were performed using SPSS 15.0 for Windows.

Frequency of pancreatic metastasis
==================================

The precise prevalence of pancreatic metastasis is not clear. The reported frequency of pancreatic metastases was 1.6% in 4955 adult autopsy cases.[@b9-rado-48-01-11] This rate was 5.9% in 1740 autopsies of another study.[@b11-rado-48-01-11] Pancreas metastasis has been observed in 25 (2.1%) patients of 1172 pancreatic endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA).[@b19-rado-48-01-11] This rate was, respectively 10.7%, 2.4%, and 0.7% in different studies.[@b18-rado-48-01-11],[@b20-rado-48-01-11],[@b21-rado-48-01-11] Because the radiological examination is generally conducted in an early stage, the occurrence of pancreatic metastases in cancer patients undergoing computerised tomography (CT) should be significantly lower than in patients who have died of cancer.[@b22-rado-48-01-11] On the other hand, the metastases have been only detected at the microscopic level in 25% of the patients in autopsy series.[@b9-rado-48-01-11]

The primary site of metastatic pancreatic tumour differs according to the study. The most common site can be lung carcinoma, renal cell carcinoma, colon carcinoma, or stomach carcinoma.[@b9-rado-48-01-11]--[@b13-rado-48-01-11],[@b15-rado-48-01-11],[@b16-rado-48-01-11],[@b18-rado-48-01-11],[@b19-rado-48-01-11],[@b21-rado-48-01-11]--[@b27-rado-48-01-11] Mesa *et al.* reviewed all secondary tumours of pancreas in literature by Medline between 1966 and 2003.[@b18-rado-48-01-11] Lungs (18.7%), gastrointestinal tract (17.7%), kidneys (16.3%), breasts (10.6%), and lymphomas (7.9%) were the most frequent secondary neoplasms in 699 cases. The reported incidence by site of origin reflects the overall incidence of cancers in the general population. However, there are a disproportionately high number of reports of metastases from renal cell carcinoma. Another review in 2004 showed that the predominant primary tumour was renal cell carcinoma in 150 cases (45%), followed by lung carcinoma in 49 cases (14.7%), breast carcinoma in 25 cases (7.5%), and colon cancer in 22 cases (6.6%).[@b28-rado-48-01-11] Sweeney *et al.* searched PubMed using the terms "pancreatic metastasis" and "cancer metastatic to the pancreas" after 2004.[@b29-rado-48-01-11] They found that the most common primary tumour site was kidney (70.5%), followed by breast (6.8%), lung (5.9%), and colorectal (5.5%) for 220 patients. It has been suggested that pancreatic metastases may arise from local lymphatic or venous dissemination because the pancreas and kidneys are located close to one another within the retroperitoneal compartment.[@b25-rado-48-01-11]

Smith reviewed the incidence of metastasis to the hepatic-pancreatic-biliary axis in primary carcinoma of the lung.[@b30-rado-48-01-11] A total of 679 (10%) patients were found in 6807 autopsies between 1929 and 1975. On searching medical records of 850 patients with lung cancer, 26 (3.1%) cases were identified with pancreatic metastasis.[@b31-rado-48-01-11] Fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) is a powerful tool for oncology imaging. Pancreatic metastases were found in 1.9% of 573 cases with lung cancer by FDG-PET/CT study.[@b7-rado-48-01-11] However, only one of the pancreatic lesions had histological confirmation in this study. Because primary pancreatic cancer and pancreatitis also show FDG accumulation, the actual rate of metastasis to pancreas in lung cancer may be lower than 1.9 percent. A pathological confirmation is sometimes considered unjustifiable both from the patient's and an economic standpoint. This problem also alters the true incidence of metastatic disease of the pancreas.

The most common histological type of lung cancer that is related to pancreatic metastasis was reported as small cell lung cancer, followed by large cell carcinoma, squamous cell carcinoma, and adenocarcinoma.[@b12-rado-48-01-11],[@b30-rado-48-01-11],[@b32-rado-48-01-11]--[@b35-rado-48-01-11] For metastasis-induced acute pancreatitis patients with lung cancer, the rate of small cell carcinoma to non-small cell carcinoma was 15/18 in one study and 5/15 in another study.[@b8-rado-48-01-11],[@b36-rado-48-01-11]

Clinical picture
================

The symptoms produced by metastasis to the pancreas are variable. Most patients (50--83%) are free of organ-specific complaints (abdominal pain, jaundice, abdominal discomfort, weight loss) when the metastasis are detected incidentally on CT during periodic clinical surveillance or follow-up. [@b25-rado-48-01-11],[@b37-rado-48-01-11],[@b38-rado-48-01-11] Metastases can directly invade pancreatic ductal epithelium and thus may clinically mimic primary pancreatic adenocarcinoma.[@b37-rado-48-01-11] Organ-related clinical symptoms were observed in only 6 of our 18 patients.[@b10-rado-48-01-11] In a review of 220 patients, the most common presenting symptoms were jaundice (25.2%), and abdominal pain (11.4%). In their survey, 27.6% of the patients were asymptomatic.[@b29-rado-48-01-11] Male/female ratio was 48/22 in our survey. Mean age was 59±10 (range 37--83). The most common location was the left lung (59%).

Time of metastasis
------------------

Pancreatic metastasis generally constitutes a late manifestation of widespread disseminated metastasis in cancer patients.[@b39-rado-48-01-11] In Mayo Clinic series, only 27 of 1357 patients (2%) with solitary pancreatic masses had secondary pancreatic tumour.[@b26-rado-48-01-11] For small cell lung cancer, all ten patients in autopsy series and all eight patients in clinical series are presented as disseminated disease.[@b9-rado-48-01-11],[@b38-rado-48-01-11] In addition to these 18 patients, another 49 patients ([Table 1](#t1-rado-48-01-11){ref-type="table"}, [2](#t2-rado-48-01-11){ref-type="table"}, and [3](#t3-rado-48-01-11){ref-type="table"}) also had other metastases, but 10 had solitary pancreatic metastasis. Consequently, the rate of solitary pancreatic metastasis to disseminated metastases was 10/67. The overall survival of these patients may be lower because of the extensive disease. The presence of pancreatic metastases indicates the visceral widespread and is of ominous prognostic importance. Median survival for 4 patients who had not other metastasis was 8.25 months but 1.7 months for 29 patients with extensive disease in our survey.

Jaundice due to small cell lung cancer
--------------------------------------

Lung cancer can cause biliary tract obstruction by metastasising to lymph nodes in the porta hepatis, pancreas or hepatic parenchyma.[@b40-rado-48-01-11] Johnson *et al*. reported that 12 (9.6%) among 125 patients presented with hyperbilirubinaemia with small cell lung cancer at diagnosis.[@b14-rado-48-01-11] Five of these patients had pancreatic metastasis resulting in extrahepatic biliary obstruction, and seven had diffuse hepatic metastasis without extrahepatic biliary obstruction. When compared to extrahepatic obstruction, the resolution of jaundice is more difficult in patients with diffuse hepatic metastasis. Of 19 patients reported by Smith, eight (66%) patients with small cell lung cancer had evidence of extrahepatic bile duct obstruction.[@b30-rado-48-01-11] Tumours located in the head of the gland usually cause obstructive jaundice ([Table 1](#t1-rado-48-01-11){ref-type="table"}), whereas tumours in the body and tail of the pancreas may lead to dilatation of Wirsung's duct.[@b62-rado-48-01-11] Palliative treatment by surgical biliary bypass and postoperative chemotherapy are indicated in such patients even though the patients had diffuse hepatic metastases.[@b40-rado-48-01-11] This approach may produce extended survival exceeding 4 months. [Table 1](#t1-rado-48-01-11){ref-type="table"} shows that patients treated only with surgery survive several weeks. Median survival for 6 patients treated with chemotherapy was 10.5 months but 2 weeks for 5patients treated with conservative treatment in our survey.

Acute pancreatitis due to small cell lung cancer
------------------------------------------------

Associated pathological findings in cases with secondary pancreatic tumours were reported as fat necrosis (19%), chronic pancreatitis (11%), acute pancreatitis (8%), and acute terminal pancreatitis (6%).[@b11-rado-48-01-11] Although gastric cancer has been noted the most common nonpancreatic tumour associated with pancreatitis, small cell lung carcinoma has been reported to be the most common (6 of 10 patients) lung tumour causing metastasis-induced acute pancreatitis.[@b46-rado-48-01-11],[@b47-rado-48-01-11] Some lung cancer patients with metastasis-induced acute pancreatitis, especially patients with small cell lung cancer, have no obvious symptoms, and were easily underdiag-nosed.[@b36-rado-48-01-11]

In 1973, Levine and Danovitch first described a patient with small cell lung cancer in whom acute pancreatitis developed during the progression of the malignancy.[@b48-rado-48-01-11] In a series of 40 consecutive cases of small cell cancer of the lung during the period from August 1974 to August 1977, three cases of metastasis-induced acute pancreatitis were discovered. This represented an occurrence rate of 7.5 per cent.[@b49-rado-48-01-11] Although the frequency of the clinical picture was 3.3% in another series, the rate of metastasis-induced acute pancreatitis was reported as 0.12% in the largest study consisting of 802 patients.[@b47-rado-48-01-11],[@b50-rado-48-01-11]

There are several mechanisms by which a meta-static tumour might induce acute pancreatitis. The first is the obstruction of the pancreatic duct by metastases or peripancreatic compression secondary to regional lymph nodes. This can lead to the activation of the pancreatic proteases, resulting in subsequent autolysis. The second is the vascular compromise by neoplastic destruction.[@b10-rado-48-01-11],[@b49-rado-48-01-11] In a series, almost 40% of patients with metastatic lesions had obstruction of the main pancreatic duct.[@b22-rado-48-01-11] More than half of these patients had neoplasms in the pancreatic head with associated biliary ductal obstruction.

In some patients, the possible causes of acute pancreatitis such as alcohol consumption, gallstone disease, or the use of antineoplastic agents such as ifosfamide, vinorelbine, and cisplatin can be found.[@b8-rado-48-01-11],[@b33-rado-48-01-11],[@b46-rado-48-01-11]--[@b53-rado-48-01-11] On the other hand, pathological investigation showed no evidence of metastatic tumour in some patients.[@b52-rado-48-01-11] This finding suggested that acute pancreatitis could be a paraneoplastic syndrome. Pancreatic metastasis could be confirmed by pancreatic biopsy, but it is often difficult to obtain a tissue diagnosis in these seriously ill patients due to high morbidity and false negative rate of biopsy.[@b46-rado-48-01-11] In our survey, thirteen patients (7 of them had post-mortem diagnosis) had tissue confirmation of pancreatic metastasis, but 13 patients had not had a pathological sampling of pancreatic tumour ([Table 2](#t2-rado-48-01-11){ref-type="table"}). Interestingly, we found left lung predominance (11/7) in patients with acute pancreatitis. It is necessary to investigate the lymphatic communication between the left lung and pancreas.

Treatment for tumour-induced acute pancreatitis is initially supportive. In patients with mild pancreatitis, chemotherapy may favourably influence the recovery from pancreatitis. However, chemotherapy is poorly tolerated by patients with severe pancreatitis and it is therefore inadvisable in patients with high (\>3) Ranson scores.[@b50-rado-48-01-11] Of the two cases reported, one patient receiving supportive treatment died in one month, and the other patient survived only seven weeks in spite of palliative abdominal radiotherapy.[@b48-rado-48-01-11] There was only one study that investigated the prognostic factors for metastasis-induced acute pancreatitis patients with lung cancer.[@b36-rado-48-01-11] Chemotherapy and performance status have been found to be significant factors for survival. In our survey median survival for 6 patients treated with chemotherapy was 6 months, but two weeks for 5 patients treated with conservative treatment.

Radiographic features
=====================

Lesions are primarily diagnosed on radiographic techniques. Imaging techniques are able to delineate the mass and evaluate its size and lymph node status, as well as the extent of vascular invasion. Pancreatic metastasis must be distinguished from local invasion of malignant gastrointestinal tumours. Although abdominal ultrasound is the first-line imaging, CT is the most frequently used method for studying pancreatic cancer.[@b67-rado-48-01-11] Ultrasonography also helps to distinguish the aetiology of the common causes of pancreatitis and it is important to exclude cholelithiasis if chemotherapy is to be considered.[@b54-rado-48-01-11]

The sensitivity of abdominal ultrasound in the detection of all tumours in the pancreas was found as 89% in a prospective study.[@b68-rado-48-01-11] The sonographic appearance of metastasis appeared as homogenous, well-demarcated solid lesion with a more hypoechoic internal structure than the pancreatic parenchyma. The pancreatic duct is usually not dilated. Although metastases can be hypovascular or hypervascular depending on the primary malignancy, a pancreatic mass rich in blood flow, as indicated by colour Doppler ultrasound, is more likely to be a metastasis than a primary pancreatic carcinoma.[@b39-rado-48-01-11],[@b69-rado-48-01-11],[@b70-rado-48-01-11] The metastatic lesion from a renal cell carcinoma is usually highly vascular, and contrast-enhanced ultrasound or angiography is very useful for diagnosis.[@b12-rado-48-01-11] Endoscopic ultrasound can show invisible metastases in abdominal ultrasound.[@b55-rado-48-01-11] Interestingly, abdominal ultrasound can show invisible metastases in CT.[@b56-rado-48-01-11] Endoscopic ultrasound features of primary pancreatic cancer and metastatic lesion were similar with respect to tumour size, echogenicity, or consistency. Although endoscopic ultrasound is probably superior for detection of small tumours, helical CT appears equal to or perhaps even better than endoscopic ultrasound for staging pancreatic neoplasms.[@b20-rado-48-01-11]

For 12 patients with pancreas metastasis, abdominal ultrasonography had reported hypoechoic lesion in 6 patients, a hypertrophic aspect involving the head of the pancreas with dilatation of the main pancreatic duct in one patient, and an aspect suggestive of acute pancreatitis in one patient.[@b15-rado-48-01-11] In their study, abdominal CT was performed in 19 patients and revealed tumours in 13 patients, increased pancreatic volume in 5 patients, and an aspect compatible with pancreatitis in one patient. CT technology has improved greatly over the last decade. For primary pancreatic cancer, an accuracy of 99% has been reported for prediction of vascular invasion by tumour with multi-detector helical CT (MDCT).[@b71-rado-48-01-11] Although the sensitivity of modern MDCT scanners in demonstrating pancreatic metastasis is still not known, MDCT with 2D multi-planar reconstructions (MPR) and three-dimensional rendering allows detection of lesions that are not visible on routine CT images.[@b53-rado-48-01-11] In a study of 11 cases, nearly 30% of pancreatic metastases were missed on routine transaxial images and detected only on thin slice or MPR images.[@b7-rado-48-01-11] There was only one study that investigated the diagnostic performance of MDCT in pancreatic metastases.[@b67-rado-48-01-11] All metastatic lesions in 17 patients, ranged between 8 and 40 mm, were demonstrated by MDCT.

Precontrast CT images of the pancreas show either isodense or hypodense lesions when compared to the normal parenchyma, with rare regions of calcification.[@b69-rado-48-01-11] Solitary metastases typically demonstrate areas of low attenuation (probably indicative for necrotic foci) on contrast enhanced CT, while the diffuse form of metastasis remains isodense following intravenous contrast medium.[@b10-rado-48-01-11],[@b41-rado-48-01-11] A peripheral rim of enhancement after intravenous contrast medium is usually demonstrated. Rim enhancement is especially common in lesions larger than 1.5 cm in size, whereas smaller tumours display a more uniform vascular pattern.[@b41-rado-48-01-11] Although some authors did not observe a correlation between tumour size and pattern of enhancement, they also found a peripheral enhancement in 73% of the patients.[@b24-rado-48-01-11] The peripheral enhancement of tumour tissue observed in many cases reflects a degree of vascular perfusion that is not typical of primary pancreatic adenocarcinoma, whereas ductal adenocarcinoma of the pancreas typically appears as a uniformly nonenhancing mass at contrast-enhanced.[@b22-rado-48-01-11],[@b24-rado-48-01-11]

CT can occasionally fail to show subtle differences in attenuation between normal pancreatic tissue and non-necrotic or non-cystic neoplastic tissue.[@b23-rado-48-01-11] Of 34 patients with autopsy-proven secondary tumour, pancreatic abnormalities were documented on non-helical abdominal CT only in 18 (53.8%) cases. Initial CT of the pancreas can be normal in appearance in patients with metastasis.[@b10-rado-48-01-11] Lymphatic metastasis of the pancreas can occur without any tumour formation, what is often seen in stomach carcinoma.[@b11-rado-48-01-11]

On magnetic resonance imaging, pancreatic metastases typically appear hypointense and well circumscribed compared with normal gland tissue on unenhanced T1-weighted images, both with and without fat saturation. Following intravenous gadopentetate dimeglumine administration, a rim of enhancement is usually visible in larger lesions and homogenous enhancement is typically demonstrated in smaller tumours. On T2-weighted images, the lesions are slightly heterogeneous and moderately hyperintense. Hypointense nodules are sometimes visible on T2-weighted images, especially in the diffusely enlarged type.[@b38-rado-48-01-11],[@b41-rado-48-01-11]

A definitive diagnosis requires a pathologic examination of a biopsy or surgical specimen. Endoscopic ultrasound-guided fine-needle aspiration has become the preferred method for cytologic-tissue acquisition of pancreatic masses, especially following equivocal CT imaging.[@b69-rado-48-01-11] Nevertheless, the histological distinction between primary pancreatic cancer and metastatic tumour is sometimes difficult to establish.[@b15-rado-48-01-11]

Radiological pattern of metastasis
==================================

The majority of overall metastatic lesions were found in the head of the pancreas.[@b16-rado-48-01-11],[@b20-rado-48-01-11],[@b29-rado-48-01-11],[@b32-rado-48-01-11] For lung cancer, some authors reported that the majority of metastatic lesions were observed in the body or the head of the pancreas.[@b33-rado-48-01-11],[@b38-rado-48-01-11] However, our review showed that the most common macroscopic location is the head (76%) of the gland for small cell lung cancer ([Table 1](#t1-rado-48-01-11){ref-type="table"}, [Table 2](#t2-rado-48-01-11){ref-type="table"}, and [Table 3](#t3-rado-48-01-11){ref-type="table"}). The body was the second most common site (15%) for solitary involvements.

Three patterns of metastatic involvement of the pancreas have been described. The first and most common, reported in 50--80% of cases, is that of a single localised mass.[@b19-rado-48-01-11] A second pattern of diffuse pancreatic enlargement has been reported in 15--44% of cases. Diffuse enlargement is characterised by a diffuse infiltration of malignant cells along the interlobular septa, which causes the destruction of large parts of the pancreatic lobules.[@b23-rado-48-01-11] The gland has homogenous density in CT appearance. The third pattern is multiple pancreatic nodules (10--44%), represented by many small nodules which can coalesce occasionally into larger masses.[@b12-rado-48-01-11],[@b22-rado-48-01-11],[@b23-rado-48-01-11],[@b37-rado-48-01-11] The attenuation of the neoplastic nodules may be variable.[@b49-rado-48-01-11]

Solitary nodule was the usual pattern of pancreatic metastasis, both for overall tumours and for lung cancer.[@b16-rado-48-01-11],[@b22-rado-48-01-11]--[@b25-rado-48-01-11],[@b31-rado-48-01-11] Although the most common cause of diffuse infiltrative type of metastasis reported is small cell carcinoma of the lung \[[@b10-rado-48-01-11]\], in our survey of 50 patients with small cell lung cancer, we observed a solitary nodule in 29 patients (57%), multiple nodules in 14 patients (27%), and diffuse enlargement in 8 (16%) the patients. Radiological pattern can be related to the invasiveness of metastatic carcinoma.[@b10-rado-48-01-11] Interestingly, we found that diffuse enlargement is the most common pattern (50%) in patients with acute pancreatitis ([Table 2](#t2-rado-48-01-11){ref-type="table"}). On the other hand, the most common type of metastasis was diffuse involvement in histological examination.[@b10-rado-48-01-11]

Conclusions
===========

The frequency of pancreatic metastasis varies between 1.6% and 10.6% in autopsy studies. Secondary tumours constitute 3--17% of all pancreatic tumours in clinical studies, but 43--65% in autopsy studies. The most common pattern for small cell lung cancer is a single localised mass in the head of the gland. The primary tumour is generally found in the left lung. Less than 15% of the patients had solitary pancreatic metastasis but other extensive disease. In spite of the advent of other imaging modalities, CT is still the gold standard for the evaluation of pancreatic pathology. In the patients with jaundice, systemic chemotherapy might resolve the obstruction with symptomatic relief for the patient. Metastasis-induced acute pancreatitis can be a lethal event, and the diagnosis should be considered in any patient with known small cell carcinoma in whom an acute abdomen develops. Because of the aggressive nature of the tumour, all patients who had an appropriate performance status should receive systemic chemotherapy. The prognosis is better in patients with solitary pancreatic metastasis.

###### 

The characteristics of the patients with pancreatic metastasis-induced obstructive jaundice in small cell lung cancer

  **References**                                 **Gender**   **Age**   **Side of primary tumour**   **Location of secondary tumour**   **Pattern of metastasis**   **Other metastases**   **Treatment**                                                       **Response to chemotherapy**   **Survival**
  ---------------------------------------------- ------------ --------- ---------------------------- ---------------------------------- --------------------------- ---------------------- ------------------------------------------------------------------- ------------------------------ --------------
  Smith HJ.[@b30-rado-48-01-11]                  NA           NA        NA                           NA                                 NA                          Present                Supportive                                                          NA                             4 weeks
  Smith HJ.[@b30-rado-48-01-11]                  NA           NA        NA                           NA                                 NA                          Present                cholecystojejunostomy                                               NA                             10 weeks
  Smith HJ.[@b30-rado-48-01-11]                  NA           Na        NA                           Na                                 NA                          Present                Supportive                                                          NA                             \<2 weeks
  Jeong IB *et al.*[@b34-rado-48-01-11]          Female       65        Left                         Head                               multiple                    Absent                 Percutaneous transhepatic biliary drainage following chemotherapy   Complete remission             \>11 months
  Howe HR *et al.*[@b35-rado-48-01-11]           Female       40        Right                        Head                               solitary                    Present                Choledochojejunostomy, irradiation, chemotherapy                    Minimal response               1 month
  Howe HR *et al.*[@b35-rado-48-01-11]           Male         53        Right                        Head                               solitary                    Present                Gastrojejunostomy + cholecystojejunostomy                           NA                             \<2 weeks
  Obara M *et al.*[@b40-rado-48-01-11]           Male         69        Left                         Head                               multiple                    Present                Percutaneous transhepatic biliary drainage followed chemotherapy    Partial remission              10 months
  Kotan C *et al.*[@b41-rado-48-01-11]           Male         46        Right                        Head                               solitary                    Present                Pancreaticoduodenectomy followed chemotherapy                       NA                             11 months
  Sakar A *et al.*[@b42-rado-48-01-11]           Male         64        Right                        Head                               solitary                    Absent                 Gastrojejunostomy + cholecystojejunostomy                           NA                             \<2 weeks
  Singh D *et al.*[@b43-rado-48-01-11]           Female       50        Right                        NA                                 multiple                    Absent                 Endoscopic retrograde cholangiopancreatography                      NA                             NA
  Ochi N *et al.*[@b44-rado-48-01-11]            Male         64        Left                         Head                               solitary                    Absent                 Endoscopic retrograde biliary drainage, chemotherapy                Partial remission              25 months
  Ochi N *et al.*[@b44-rado-48-01-11]            Male         74        Left                         Head                               solitary                    Present                Endoscopic retrograde biliary drainage, chemotherapy                Partial remission              4 months
  Dunkerley RC and Dunn GD[@b45-rado-48-01-11]   Male         72        Left                         Head                               solitary                    Present                Endoscopic retrograde biliary drainage, radiotherapy                NA                             6 months

NA = not available

###### 

The characteristics of the patients with metastasis-induced acute pancreatitis in small cell lung cancer

  **References**                                  **Gender**   **Age**   **Side of primary tumor**   **Location of secondary tumor**   **Pattern of metastasis**   **Tissue diagnosis**   **Other metastases**   **Treatment**                  **Response to chemotherapy**   **Survival**
  ----------------------------------------------- ------------ --------- --------------------------- --------------------------------- --------------------------- ---------------------- ---------------------- ------------------------------ ------------------------------ --------------
  Woo JS *et al.*[@b33-rado-48-01-11]             Female       45        Left                        Head                              multiple                    No                     Yes                    Endoscopic stenting            NA                             NA
  Liu SF *et al.*[@b36-rado-48-01-11]             Male         44        NA                          NA                                NA                          Yes                    Yes                    Chemotherapy                   NA                             7.6 months
  Liu SF *et al.*[@b36-rado-48-01-11]             Female       44        NA                          NA                                NA                          Yes                    Yes                    Chemotherapy                   NA                             3.2 months
  Liu SF *et al.*[@b36-rado-48-01-11]             Male         51        NA                          NA                                NA                          Yes                    Yes                    Chemotherapy                   NA                             9 months
  Liu SF *et al.*[@b36-rado-48-01-11]             Male         75        NA                          NA                                NA                          Yes                    Yes                    Chemotherapy                   NA                             1 month
  Liu SF *et al.*[@b36-rado-48-01-11]             Female       68        NA                          NA                                NA                          Yes                    Yes                    Conservative                   NA                             2.7 months
  Kim KH *et al.*[@b46-rado-48-01-11]             Male         63        Right                       NA                                multiple                    No                     Yes                    Conservative                   NA                             NA
  Chowhan NM *et al.*[@b47-rado-48-01-11]         Male         55        Left                        Tail                              NA                          No                     Yes                    Conservative                   NA                             2 weeks
  Chowhan NM *et al.*[@b47-rado-48-01-11]         Male         48        Right                       Head                              Solitary                    No                     Yes                    Conservative                   NA                             2 weeks
  Levine M *et al.*[@b48-rado-48-01-11]           Male         45        Right                       All                               NA                          Autopsy                Yes                    Conservative                   NA                             1 month
  Yeung KY *et al.*[@b49-rado-48-01-11]           Male         53        Left                        Head and body                     Diffuse enlargement         Autopsy                Yes                    Chemotherapy                   Partial remission              5.5 months
  Yeung KY *et al.*[@b49-rado-48-01-11]           Male         53        Right                       NA                                NA                          Autopsy                Yes                    Chemotherapy                   Partial remission              5.5 months
  Yeung KY *et al.*[@b49-rado-48-01-11]           Female       37        Right                       NA                                Diffuse enlargement         No                     No                     Chemotherapy                   Complete remission             3.5 months
  Stewart KC *et al.*[@b50-rado-48-01-11]         Female       44        Left                        Head                              Solitary                    No                     Yes                    Chemotherapy                   Partial remission              \>6 months
  Papagiannis A *et al.*[@b51-rado-48-01-11]      Male         52        Left                        NA                                Diffuse enlargement         No                     ?                      Conservative                   NA                             3 weeks
  Allan SG *et al.*[@b52-rado-48-01-11]           Female       73        Left                        NA                                Diffuse enlargement         No                     Yes                    Conservative                   NA                             5 days
  Allan SG *et al.*[@b52-rado-48-01-11]           Male         67        NA                          NA                                Diffuse enlargement         No malignity           Yes                    Conservative                   NA                             10 days
  Huang YW *et al.*[@b53-rado-48-01-11]           Female       68        Left                        NA                                Diffuse enlargement         No                     Yes                    Conservative                   NA                             9 days
  Hall M *et al.*[@b54-rado-48-01-11]             Male         67        Left                        Head                              NA                          Autopsy                Yes                    Conservative                   NA                             2 weeks
  Wurm Johansson G *et al.*[@b55-rado-48-01-11]   Female       52        NA                          Head and body                     multiple                    EUS-FNA                NA                     Biliary stent + chemotherapy   NA                             NA
  Tanaka H *et al.*[@b56-rado-48-01-11]           Female       51        Left                        Body and tail                     multiple                    No                     Yes                    Chemotherapy                   Complete remission             8 months
  Noseda A *et al.*[@b57-rado-48-01-11]           Male         58        Left                        Head                              Solitary                    No                     Yes                    Conservative                   NA                             7 weeks
  Schmitt JK[@b58-rado-48-01-11]                  Male         58        Left                        NA                                NA                          Autopsy                Yes                    Chemotherapy                   NA                             6.5 weeks
  Evans AT[@b59-rado-48-01-11]                    Female       45        Right                       NA                                Diffuse enlargement         Autopsy                Yes                    Conservative                   NA                             8 days
  Chao WC *et al.*[@b60-rado-48-01-11]            Female       65        Left                        NA                                multiple                    No                     Yes                    Conservative                   NA                             20 days
  Maclennan AC *et al.*[@b61-rado-48-01-11]       Female       56        Right                       All                               multiple                    Autopsy                ?                      Conservative                   NA                             5 weeks

NA = not available; EUS-FNA = ultrasound-guided fine-needle aspiration

###### 

Pattern of metastasis in small cell lung cancer

  **References**                               **Gender**   **Age**   **Location**       **Type**              **Other metastases**
  -------------------------------------------- ------------ --------- ------------------ --------------------- ----------------------
  Sato M *et al*.[@b7-rado-48-01-11]           male         78        body               solitary              Yes
  Sato M *et al*.[@b7-rado-48-01-11]           male         58        NA                 NA                    Yes
  Sato M *et al*.[@b7-rado-48-01-11]           male         75        NA                 NA                    Yes
  Muranaka T *et al*.[@b10-rado-48-01-11]      male         60        NA                 Diffuse enlargement   NA
  Volmar KE *et al*.[@b16-rado-48-01-11]       male         58        NA                 NA                    No
  Volmar KE *et al*.[@b16-rado-48-01-11]       male         65        NA                 NA                    No
  Mesa H *et al*.[@b18-rado-48-01-11]          NA           NA        body               NA                    NA
  Gilbert CM *et al*.[@b19-rado-48-01-11]      male         65        head               multiple              NA
  Gilbert CM *et al*.[@b19-rado-48-01-11]      male         58        head               solitary              NA
  Gilbert CM *et al*.[@b19-rado-48-01-11]      female       58        body               solitary              NA
  Layfield LJ *et al*.[@b21-rado-48-01-11]     female       57        head               NA                    NA
  Tsitouridis I *et al*.[@b24-rado-48-01-11]   male         69        Head, body, tail   multiple              Yes
  Tsitouridis I *et al*.[@b24-rado-48-01-11]   male         59        Head and tail      multiple              yes
  DeWitt J *et al*.[@b32-rado-48-01-11]        female       49        head               solitary              Yes
  DeWitt J *et al*.[@b32-rado-48-01-11]        female       75        head               solitary              Yes
  DeWitt J *et al*.[@b32-rado-48-01-11]        male         49        head               solitary              NA
  DeWitt J *et al*.[@b32-rado-48-01-11]        male         65        head               solitary              NA
  Scatarige JC *et al*.[@b37-rado-48-01-11]    male         48        head               solitary              Yes
  Scatarige JC *et al*.[@b37-rado-48-01-11]    female       68        Head and body      multiple              NA
  Xi-wen S *et al*.[@b38-rado-48-01-11]        male         74        body               solitary              Yes
  Xi-wen S *et al*.[@b38-rado-48-01-11]        male         50        NA                 solitary              Yes
  Xi-wen S *et al*.[@b38-rado-48-01-11]        male         68        NA                 solitary              Yes
  Xi-wen S *et al*.[@b38-rado-48-01-11]        male         52        NA                 solitary              Yes
  Xi-wen S *et al*.[@b38-rado-48-01-11]        female       39        NA                 solitary              Yes
  Xi-wen S *et al*.[@b38-rado-48-01-11]        male         53        NA                 solitary              Yes
  Xi-wen S *et al*.[@b38-rado-48-01-11]        male         53        NA                 multiple              Yes
  Xi-wen S *et al*.[@b38-rado-48-01-11]        male         76        NA                 solitary              yes
  Katsuura Y *et al*.[@b39-rado-48-01-11]      male         83        body               solitary              Yes
  Merkle EM *et al*.[@b62-rado-48-01-11]       male         55        tail               solitary              NA
  Das DK *et al*.[@b63-rado-48-01-11]          male         66        tail               solitary              NA
  Walshe T *et al*.[@b64-rado-48-01-11]        female       60        neck               solitary              No
  Boo SJ *et al*.[@b65-rado-48-01-11]          male         44        head               NA                    No
  Boo SJ *et al*.[@b65-rado-48-01-11]          male         75        head               NA                    No
  Boo SJ *et al*.[@b65-rado-48-01-11]          male         61        head               NA                    Yes
  Ottaiano A *et al*.[@b66-rado-48-01-11]      male         65        Head, body, tail   NA                    No

NA = not available

[^1]: Disclosure: No potential conflicts of interest were disclosed.
